RegenxBio. has filed a patent for a pharmaceutical composition designed for treating eye diseases by administering a recombinant adeno-associated virus (AAV) vector encoding a transgene to the suprachoroidal space of the eye. The composition’s viscosity ranges from 25 cP to 3×106 cP. GlobalData’s report on RegenxBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on RegenxBio, Adeno-associated virus vectors was a key innovation area identified from patents. RegenxBio's grant share as of January 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for treating eye diseases using aav vector
A pharmaceutical composition suitable for administration to the suprachoroidal space (SCS) of the eye of a human subject is disclosed in a filed patent (Publication Number: US20240024508A1). The composition includes a recombinant adeno-associated virus (AAV) vector containing an expression cassette encoding a transgene. The viscosity of the pharmaceutical composition ranges from about 25 cP to about 3×106 cP when measured at a shear rate of at most about 1 s-1. The patent claims also cover variations of the composition, including one where the transgene is an anti-human vascular endothelial growth factor (anti-VEGF) antibody, and another where the composition's clearance time, circumferential spread, thickness at the site of injection, expression level of the transgene, concentration of the transgene in the eye, and rate of transduction at the site of injection are compared to a reference pharmaceutical composition.
Furthermore, the patent claims encompass different aspects of the pharmaceutical composition, such as the inclusion of sucrose, various serotypes of adeno-associated viruses, and specific viscosity ranges. The claims also detail the potential applications of the composition in treating diseases like nAMD, dry AMD, retinal vein occlusion, diabetic macular edema, and more. Additionally, the patent covers the stability of the recombinant AAV in the composition, the infectivity of the AAV, and the level of aggregation and free DNA released by the AAV. The disclosed pharmaceutical composition can be stored at different temperatures before administration to a human subject, providing flexibility in handling and storage.
To know more about GlobalData’s detailed insights on RegenxBio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
